The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
125
Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
Unnamed facility
Aizu-Wakamatsu, Fukushima, Japan
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time frame: Up to 60 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.